Related Experiment Video
Updated: Jul 6, 2026
09:12
Isolation of Cortical Microglia with Preserved Immunophenotype and Functionality From Murine Neonates
Published on: January 30, 2014
Purinergic modulation of microglial cell activation
1Department of Pharmacology, Institute of Experimental Medicine, Hungarian Academy of Sciences, 1450, Budapest, Hungary.
Purinergic Signalling
|April 12, 2008
Summary
Microglial cells, the brain's immune cells, are activated by purines acting on specific receptors. Targeting these purinergic signaling pathways offers potential treatments for neurodegenerative and neuroinflammatory diseases.
Area of Science:
- Neuroscience
- Immunology
- Pharmacology
Background:
- Microglial cells are key players in brain immunity and CNS disease pathology.
- Microglial activation involves morphological changes, proliferation, and mediator secretion, impacting neural tissue.
- Purines released from various brain cells significantly regulate microglial functions.
Purpose of the Study:
- To explore the role of purinergic signaling in microglial activation.
- To investigate the involvement of nucleotide (P2X, P2Y) and adenosine (A1, A2A, A3) receptors in microglial responses.
- To highlight the therapeutic potential of targeting microglial purine receptors in CNS disorders.
Main Methods:
- Review of existing literature on microglial cell biology and purinergic signaling.
- Analysis of the roles of specific purine receptors (P2X, P2Y, A1, A2A, A3) in microglial function.
- Examination of evidence from disease models (ischemia, multiple sclerosis, neuropathic pain).
Main Results:
- Purines are crucial mediators regulating microglial activation through various receptor subtypes.
- Specific receptors like P2X7, P2X4, P2Y, A1, A2A, and A3 receptors are critical in microglial responses.
- Pathological roles of these receptors are evident in models of CNS diseases.
Conclusions:
- Microglial purinergic signaling is central to neuroinflammation and neurodegeneration.
- Upregulated purine receptors under pathological conditions are promising therapeutic targets.
- Targeting microglial purine receptors presents new treatment avenues for neurological illnesses.
